Search Results for: US Rheumatoid Arthritis Treatment Market
Articles
US Rheumatoid Arthritis Treatment Market Value to Reach $9.3 Billion April 1, 2015
The US treatment market for Rheumatoid Arthritis (RA) is set to increase in value from $6.4 billion in 2013 to...THERAPEUTIC FOCUS - Sarilumab Approval for Polymyalgia Rheumatica Highlights Enduring Unmet Medical Needs March 28, 2024
David A. Katz, PhD, and Robert Jacks, MBA, MSE, say a new, effective treatment option is now available, promotion of the drug will increase disease awareness, and the success encourages others in the industry to continue and expand their PMR research. However, the proportion of patients who can benefit from the drug is limited, and significant unmet needs remain for all persons suffering from PMR.
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases March 28, 2024
Mustang Bio, Inc. recently announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy....SPECIAL FEATURE - Injection Devices: Designing in Sustainability, Usability & Digitization for Patient Compliance September 5, 2023
Contributor Cindy H. Dubin, in this exclusive annual feature, highlights how leading device and drug companies are working to address the challenges of usability, sustainability, and technology to increase patient compliance.
Review of IND Application for IHL-42X by US FDA Completed; Clinical Trial for Patients With Obstructive Sleep Apnoea May Proceed August 22, 2023
Incannex Healthcare Limited recently announce it has received approval from the US FDA to conduct the company’s Investigational New Drug...Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for the Company’s Proprietary Drug for Obstructive Sleep Apnea Treatment July 6, 2023
Incannex Healthcare Limited recently announce it has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (BA/BE)...Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded US Patent June 21, 2023
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued US Patent No. 16/825,371 titled Peptide-Targeted...Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas June 14, 2023
Blue Water Biotech, Inc. recently announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain….
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis February 28, 2023
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O November 28, 2022
Incannex Healthcare Limited recently announced it has engaged multinational contract development and manufacturing organisation (CDMO) Eurofins Scientific to manufacture Incannex’s two distinct medicated….
Owen Mumford Announces on Market Release of UniSafe 1-mL Safety Device for Pre-filled Syringes Featuring Industry-First Spring-less Mechanism January 28, 2022
Owen Mumford Pharmaceutical Services recently announced its UniSafe 1-mL safety device for pre-filled syringes has been approved as a combination...CHMP Recommends Approval of RINVOQ (upadacitinib) for the Treatment of Atopic Dermatitis June 29, 2021
AbbVie recently announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion...CUSTOM DEVICE SOLUTIONS - Device Design Will Act as Competitive Distinguisher in a Post-Patent Expiry Biosimilar Market September 30, 2020
George I’ons dissects the different factors that will determine biosimilars’ adoption and pace of advancement against their original counterparts, namely clinical confidence in the biosimilar and patient confidence in the drug delivery device.
SPECIAL FEATURE - Injection Devices: Will COVID-19 Deliver Growth to the Market? September 1, 2020
Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
DEVICE DESIGN - Autoinjector Design Adjustment to Control Needle Insertion & Initial Injection Speed – Could This Positively Impact Drug Delivery? August 30, 2019
Pascal Dugand, Thomas Megard, and Séverine Duband explain how controlling the needle insertion speed can reduce the shock on the prefilled syringe, which can reduce the risk of glass breakage, and will allow a smooth transition to syringe emptying.
Huge Untapped Potential for Rheumatoid Arthritis Treatment by Targeting OX40 August 7, 2019
A new study led by experts from the University of Tsukuba first published in Annals of the Rheumatic Diseases in July found that OX40-expressing follicular helper T cells contributed to inflammation by regulating……
Road Ahead Still Difficult for Biosimilar Producers in the US Despite New FDA Guidance on Interchangeability May 17, 2019
Following news that the FDA has finalized its guidance on interchangeable biosimilars, Rose Joachim, PhD, Senior Immunology Pharma Analyst at...THERAPEUTIC FOCUS - Targeting the Novel LANCL2 Pathway Offers Potential for a Differentiated Treatment Paradigm for Autoimmune Diseases April 1, 2019
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
DNA SEQUENCING MARKET - Emerging Technologies & Applications November 7, 2016
Laurie L. Sullivan and John Bergin, MS, MBA, BCC Research Analysts, indicate that NGS has matured into an essential life science tool for genetic studies in a range of applications, and the industry is on the cusp of a second growth phase, powered by new applications in clinical diagnostics.
EXECUTIVE INTERVIEW - Cardax Inc: Delivering Nature-Identical Astaxanthin to the Market February 29, 2016
David G. Watumull, President and CEO of Cardax, Inc, discusses the company’s plans to create a new platform for products in the consumer health and pharmaceutical markets based on the delivery of nature-identical astaxanthin.
